Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: A systematic review and network meta-analysis.

医学 肺癌 酪氨酸激酶 荟萃分析 肿瘤科 酪氨酸激酶抑制剂 表皮生长因子受体 内科学 癌症研究 癌症 受体
作者
Wengang Zhang,Yujie Li,Wencheng Zhao,Zhiyi Guo,Qianqian Zhang,Bing Bo,Maoying Guan,Xuyang Chen,Ye Li,Zhimin Chen,Hao Wang,Lishu Zhao,Kandi Xu,Xinyue Liu,Yujin Liu,Yuhang Li,Lihua Huang,Jing Nie,Yayi He
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl): 3075-3075
标识
DOI:10.1200/jco.2025.43.16_suppl.3075
摘要

3075 Background: Targeted therapy with EGFR tyrosine-kinase inhibitors (TKIs) is the preferred first-line treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC), but acquired resistance inevitably occurs in almost all responding individuals. We aimed to comprehensively review the literature to investigate the efficacy and safety of distinct regimens in the subsequent-line setting, thereby identifying the optimal regimen for these TKI-resistant NSCLC patients. Methods: The PubMed, Embase, Cochrane Library databases, and abstracts of ASCO, ESMO, and WCLC were searched from database inception to 3 November 2024, to identify eligible randomized controlled trials (RCTs) that assessed distinct regimens for individuals with advanced EGFR-mutated NSCLC who progressed on TKIs. The outcomes of progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and grade 3 or higher adverse events (≥3AEs) were compared and ranked in overall patients and various subgroups among 8 regimens by network meta-analysis and the surface under the cumulative ranking curve, respectively. The protocol is registered with PROSPERO, CRD42024601619. Results: 14 RCTs, involving 3177 participants and 8 treatment regimens (chemotherapy plus ivonescimab (PD-1/VEGF inhibitor) [CT+IVO]; CT+amivantamab+lazertinib [CT+AMI+LAZ], CT+immunotherapy+bevacizumab [CT+IO+BEV], CT+AMI, CT+BEV, CT+IO, CT, and IO), were included. In overall patients, the most pronounced PFS benefit was observed with the CT+IVO, followed by CT+AMI+LAZ, CT+IO+BEV, and CT+AMI, ranked second, third, and fourth, respectively. In terms of OS, the regimen of CT+AMI ranked the best, followed by CT+IVO. However, the comparisons of OS among different regimens did not reach statistical significance, possibly due to immature data. The results for ORR and DCR were similar to those for OS, with CT+AMI topping the rankings, followed by CT+AMI+LAZ. In terms of safety, the incidence of ≥3AEs was highest in CT+AMI+LAZ, followed by CT+AMI. In subgroup analysis, CT+IVO demonstrates stable PFS benefits across clinicopathological characteristics, ranking first in most subgroups. Due to the unavailability of OS subgroup data in most RCTs, many regimens were missing in the OS subgroup analysis. Conclusions: Integrating the results of different clinical outcomes and subgroup analyses, we conclude that CT+IVO is the optimal treatment option with an acceptable safety profile for patients with advanced EGFR-mutated NSCLC who have progressed on TKIs. CT+AMI+LAZ and CT+AMI are alternative subsequent line options as well, with superior efficacy compared to immunotherapy-based or chemotherapy regimens, yet elevated toxicity profiles requiring vigilant management.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
留蓝发布了新的文献求助10
刚刚
Owen的应助被夏梓硕采纳,获得10
刚刚
周林发布了新的文献求助10
1秒前
1秒前
wl完成签到,获得积分10
2秒前
humble发布了新的文献求助10
2秒前
羊羊羊完成签到,获得积分20
2秒前
白术完成签到,获得积分10
2秒前
4秒前
4秒前
jjj完成签到,获得积分10
5秒前
wanci的应助被Rauf采纳,获得10
5秒前
CHEN完成签到,获得积分10
6秒前
GIN的应助被胡萝卜卜采纳,获得10
6秒前
科研通AI6.4的应助被WYF1996采纳,获得10
7秒前
科研通AI65的应助被科研通管家采纳,获得10
7秒前
CipherSage的应助被科研通管家采纳,获得10
7秒前
大模型的应助被科研通管家采纳,获得10
7秒前
xlxl完成签到,获得积分10
7秒前
无极微光的应助被科研通管家采纳,获得20
7秒前
AAAA完成签到,获得积分10
7秒前
ding的应助被科研通管家采纳,获得10
7秒前
桐桐的应助被科研通管家采纳,获得10
7秒前
杜若完成签到,获得积分10
7秒前
酷波er的应助被科研通管家采纳,获得10
7秒前
8秒前
CipherSage的应助被科研通管家采纳,获得10
8秒前
JamesPei的应助被科研通管家采纳,获得10
8秒前
零负一的应助被科研通管家采纳,获得10
8秒前
自然的冥王星完成签到,获得积分10
8秒前
无极微光的应助被科研通管家采纳,获得20
8秒前
8秒前
8秒前
9秒前
深情安青的应助被科研通管家采纳,获得10
9秒前
搜集达人的应助被科研通管家采纳,获得10
9秒前
打工人完成签到 ,获得积分10
10秒前
Pululuu发布了新的文献求助10
10秒前
Y18085650540完成签到,获得积分10
12秒前
晴天完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193348
求助须知:如何正确求助?哪些是违规求助? 9579548
关于积分的说明 21866040
捐赠科研通 7792906
什么是DOI,文献DOI怎么找? 3437242
关于科研通互助平台的介绍 2560702
邀请新用户注册赠送积分活动 2484066